ESPR Esperion Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ESPR matters now
Esperion Therapeutics, Inc. (ESPR) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.18 with -0.31% on the session and $661.1M in market capitalization; recent performance reads 1-month +0.64% and YTD -14.86%.
The latest financial table shown here is Q1 2026, with revenue of $80.1M, net income of $-25.2M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.8%.
The latest indexable market news headline is "Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger" from MarketBeat.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.16; recent insider activity includes Halladay Benjamin filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.57
P/S
1.57
EV/EBITDA
18.83
DCF Value
$-64.90
FCF Yield
-2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.0%
Operating Margin
18.1%
Net Margin
-1.8%
ROE
2.0%
ROA
-1.6%
ROIC
30.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $80.1M | $-25.2M | $-0.10 |
| Q4 2025 | $168.4M | $61.8M | $0.22 |
| FY 2025 | $403.1M | $-22.7M | $-0.11 |
| Q3 2025 | $87.3M | $-31.3M | $-0.16 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$3.19
Target (Median)
$3.16
Target Range
$3.16 - $3.28
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.07
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.